Standout Papers
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer (2010)
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer (2012)
- Epithelial ovarian cancer (2019)
- Endometrial cancer (2005)
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial (2014)
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial (2014)
- Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study (2000)
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG (2006)
- Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer (2008)
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) (2011)
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse (2010)
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial (2016)
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline (2016)
- Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline (2016)
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019)
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I (2021)
Immediate Impact
3 by Nobel laureates 4 from Science/Nature 67 standout
Citing Papers
Designing antibodies as therapeutics
2022 Standout
Endometriosis: Etiology, pathobiology, and therapeutic prospects
2021 Standout
Works of Ignace Vergote being referenced
Clinical Outcome After Radical Excision of Moderate—Severe Endometriosis With or Without Bowel Resection and Reanastomosis
2013
Surgical treatment of deeply infiltrating endometriosis with colorectal involvement
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Ignace Vergote | 20791 | 13074 | 12303 | 847 | 36.9k | |
| Robert C. Bast | 13430 | 13462 | 3993 | 583 | 44.0k | |
| Robert L. Coleman | 9133 | 7443 | 5543 | 657 | 22.5k | |
| Bradley J. Monk | 9006 | 8253 | 7806 | 572 | 22.2k | |
| Robert A. Soslow | 10108 | 4252 | 10830 | 422 | 23.0k | |
| Michael Friedländer | 9605 | 15324 | 2542 | 486 | 26.8k | |
| Frédéric Amant | 8626 | 6917 | 8392 | 530 | 21.0k | |
| Douglas A. Levine | 7181 | 6587 | 4399 | 253 | 21.8k | |
| Karen H. Lu | 8090 | 6678 | 5085 | 425 | 21.0k | |
| Jalid Sehouli | 7543 | 5694 | 3644 | 830 | 18.5k | |
| Maurie Markman | 7701 | 6320 | 2663 | 412 | 19.5k |
All Works
Login with ORCID to disown or claim papers
Loading papers...